Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR132 | Q9UNW8 | 6/20 | 0.59 |
| ▸ | MAOB | P27338 | 2/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.57 |
| ▸ | MMP13 | P45452 | 1/20 | 0.57 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.56 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | GPR34 | Q9UPC5 | 5/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | CMKLR2 | P46091 | 1/20 | 0.52 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5921827 | 0.90 | GPR132 (0.63) | GPR132MAOBMAOAITGB3ITGA2B | |
| SCHEMBL5921821 | 0.90 | GPR132 (0.63) | GPR132MAOBMAOAITGB3ITGA2B | |
| SCHEMBL6029880 | 0.85 | GPR132 (0.73) | GPR132ITGB3ITGA2BGPR34PTPN1 | |
| SCHEMBL6030433 | 0.85 | GPR132 (0.65) | GPR132KMT2AGPR34PTPN1CMKLR2 | |
| SCHEMBL5927205 | 0.84 | GPR132 (0.72) | GPR132ITGB3ITGA2BGPR34PTPN1 | |
| SCHEMBL1123243 | 0.84 | GPR132 (0.72) | GPR132ITGB3ITGA2BGPR34PTPN1 | |
| SCHEMBL1122833 | 0.84 | GPR132 (0.72) | GPR132ITGB3ITGA2BGPR34PTPN1 | |
| SCHEMBL6030407 | 0.84 | GPR34 (0.70) | GPR132MAOBMAOAGPR34PTPN1 | |
| SCHEMBL6030231 | 0.84 | GPR34 (0.70) | GPR132MAOBGPR34PTPN1CMKLR2 | |
| SCHEMBL6030436 | 0.84 | GPR132 (0.63) | GPR132ITGB3ITGA2BGPR34PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060247260-A1 | Bis (hetero) aryl carboxamide derivatives for use as PG12 antagonists | BAYER HEALTHCARE AG (DE) | 2006-11-02 | — | — | US | claimed |
| EP-1594846-A1 | BIS(HETERO)ARYL CARBOXAMIDE DERIVATIVES FOR USE AS PGI2 ANTAGONISTS | Bayer HealthCare AG (DE) | 2005-11-16 | — | — | EP | claimed |
| WO-2004069805-A1 | BIS(HETERO)ARYL CARBOXAMIDE DERIVATIVES FOR USE AS PGI2 ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2004-08-19 | — | — | WO | claimed |
| US-20060247260-A1 | Bis (hetero) aryl carboxamide derivatives for use as PG12 antagonists | BAYER HEALTHCARE AG (DE) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247260-A1 | Bis (hetero) aryl carboxamide derivatives for use as PG12 antagonists | HRH2, BPHL, HRH1 | GPR132 68/4885MAOB 2096/4885MAOA 1717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.